Ten Things to Know About the New FDA Approved Alzheimer’s Drug, Kisunla (donanemab)

Pat Bishara, 79, was diagnosed with mild cognitive impairment in late 2017. Beginning in 2021, she participated in both the phase 3 trial and the extension trial for donanemab. Along with the monthly infusion, she was also … [Read more...]

Print This Page
Skip to content